VCYT

Veracyte, a molecular diagnostic company, has demonstrated a strong streak of beating earnings estimates in its last two quarters, with an average beat of 39.26%. The company has a positive Earnings ESP of +4.65% combined with a Zacks Rank #3 (Hold), suggesting another potential earnings beat is likely when it reports on November 4, 2026. Stocks with this combination historically beat consensus estimates nearly 70% of the time.

The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies stocks likely to beat earnings estimates by comparing analyst revisions. When combined with a Zacks Rank #3 or stronger, stocks posted positive surprises 70% of the time with ~28% average annual returns. Two medical stocks highlighted as examples are Veracyte (VCYT) with a +4.65% ESP and Idexx Laboratories (IDXX) with a +0.59% ESP, both positioned to potentially beat their upcoming earnings reports.

Veracyte announced that eight studies utilizing its Decipher Prostate Genomic Classifier test will be presented at the 2026 ASTRO Annual Meeting in Boston (September 26-30). The presentations include six oral presentations and two posters examining the test's prognostic and predictive value in assessing prostate cancer risk and identifying patients who may benefit from treatment intensification, including androgen-deprivation therapy combined with radiation.